SHL Medical partners with SMC Ltd. to support assembly, labeling and packaging of Molly

Zug, Switzerland - SHL Medical (hereinafter referred to as "SHL"), a global leader in the design, development, and manufacturing of self-injection solutions, today announced a strategic collaboration with global healthcare contract manufacturer SMC Ltd. (hereinafter referred to as "SMC").

SHL Medical's Molly modular platform is a proven, single-dose autoinjector technology designed to help pharmaceutical and biotechnology companies reduce development risk and accelerate time to market. Available in both 1.0 mL and 2.25 mL configurations, Molly is compatible with leading pre-filled syringe formats and supports both standard and customized device designs.

Through final assembly, labeling, and packaging services for SHL's Molly autoinjector, SMC will provide pharmaceutical and biotechnology companies with an established U.S. manufacturing solution to support programs leveraging the Molly platform.

SHL Medical's Molly platform is a 2-step, single-dose autoinjector technology developed to help pharma and biotech companies reduce initial investments and expedite development timelines. More than 210 million devices have reached patients since Molly's launch in 2016.

Designed to support the unique requirements of drug-device combination products, SMC's manufacturing operations include dedicated production areas, specialized automation technologies, experienced personnel, and comprehensive quality systems for assembly, labeling, and packaging activities.

"Pharmaceutical companies are looking for proven device platforms combined with manufacturing solutions that can support their programs as they scale," said Chetan N. Patel, Owner and CEO, SMC Ltd. "By adding the Molly platform to our standard Final Assembly, Labeling and Packaging offerings, we can provide customers with a more streamlined path to access an established autoinjector technology together with the automation, manufacturing infrastructure and operational expertise needed to support commercialization."

Together with SHL Medical's Molly autoinjector platform, these capabilities provide customers with a well-defined pathway to scale from product development into reliable commercial manufacturing and supply.

"Together with SMC, we are making it easier for pharmaceutical companies to access a proven autoinjector platform and the capabilities needed to bring products to market," emphasized Markus Puusepp, Chief Growth Officer, SHL Medical. "Our collaboration and the availability of scalable final assembly, labeling and packaging infrastructure for Molly at SMC, helps customers de-risk development, accelerate scale-up, and move confidently toward commercialization."

About SHL Medical 

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose - Enabling Patients' Independence - SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.   

Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. 

For additional information, visit http://www.shl-medical.com/

Media contact: [email protected]